Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter and full year ended December 31, 2013.
“Our first year as a public company has been a productive one for Tetraphase as we advanced our lead antibiotic candidate, eravacycline, into Phase 3 development and confirmed that we will be pursuing two therapeutic indications for regulatory approval,” said Guy Macdonald, Tetraphase President and Chief Executive Officer.
Help employers find you! Check out all the jobs and post your resume.
